7MM Human Immunodeficiency Virus (HIV) Epidemiology Forecasts 2023-2033
04. Februar 2025 09:12 ET
|
Research and Markets
Dublin, Feb. 04, 2025 (GLOBE NEWSWIRE) -- The "Human Immunodeficiency Virus (HIV): Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering. This report provides...
Global Diagnostics and Therapeutics for HIV Market Expected to Reach $39.3 Billion by 2028: Advancements in Diagnostic Technologies Drive Growth
01. November 2023 05:58 ET
|
Research and Markets
Dublin, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The "Diagnostics and Therapeutics for HIV: Global Markets" report has been added to ResearchAndMarkets.com's offering. The global diagnostics and...
Fusion Inhibitors Market Revenue to Cross USD 7.2 billion by 2031, Exhibiting a 14.2% CAGR: TMR Report
04. Oktober 2023 03:52 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The fusion inhibitors market attained US$ 295.3 million in 2021. The market is likely to...
Global HIV Drugs Market Research Report 2023-2031: Antiretroviral Therapy (ART) Emerging as Pivotal Tool in Managing HIV and Enhancing Well-Being
03. Oktober 2023 06:58 ET
|
Research and Markets
Dublin, Oct. 03, 2023 (GLOBE NEWSWIRE) -- The "Global HIV Drugs Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.The global HIV drugs market value...
HIV Drugs Global Market Research Report 2023
27. März 2023 10:28 ET
|
Research and Markets
Dublin, March 27, 2023 (GLOBE NEWSWIRE) -- The "HIV Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global HIV drug market is expected to grow from...
Insights on the HIV/AIDS Drugs Global Market to 2027 - Increasing R&D Initiatives for the Development of the Long-Acting Suppression Antiretroviral Therapy Presents Opportunities
14. September 2022 07:43 ET
|
Research and Markets
Dublin, Sept. 14, 2022 (GLOBE NEWSWIRE) -- The "Global HIV/AIDS Drugs Market (2022-2027) by Medication Class, Distribution Channel, Geography, Competitive Analysis and the Impact of Covid-19 with...
Global and Historical Trends - HIV Epidemiology Forecasts to 2029
22. Februar 2022 05:53 ET
|
Research and Markets
Dublin, Feb. 22, 2022 (GLOBE NEWSWIRE) -- The "Human Immunodeficiency Virus (HIV) - Epidemiology Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. The total prevalent...
Human Immunodeficiency Virus Type-1 (HIV-1) Industry Landscape Report 2021-2030 Featuring Insights Into Lenacapavir (GS-6207), GSK3640254 (GSK'254), and MK-8591A (Islatravir/doravirine; DOR/ISL)
21. Dezember 2021 09:03 ET
|
Research and Markets
Dublin, Dec. 21, 2021 (GLOBE NEWSWIRE) -- The "Human Immunodeficiency Virus Type-1 (HIV-1) - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to...
Exavir Therapeutics announces preclinical data demonstrating complete elimination of HIV from human cells with LNP-delivered Tat-targeted CRISPR-Cas9
10. November 2021 07:30 ET
|
Exavir Therapeutics
Early candidate from XVIR-TAT series demonstrated genetic elimination of HIV and robust anti-retroviral activity with CRISPR-Cas9 based excision Exavir lipid nanoparticles (LNPs) with mRNA...
Exavir Therapeutics announces the publication of preclinical data for the ultra-long-acting integrase inhibitor XVIR-110 in Nature Communications, affirming its unique pharmacokinetic profile and potential as a best-in-class yearly antiretroviral
08. Juni 2021 07:00 ET
|
Exavir Therapeutics
With a single administration, XVIR-110, a nano-formulated prodrug integrase inhibitor, provided year-long plasma drug levels sufficient for HIV treatment and prophylaxis in animal models Studies...